Low ER+ Breast Cancer
Authors:
Open Access
- 1 May 2014
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 141 (5) , 697-701
Abstract
Objectives. Estrogen receptor (ER) level can be semiquantified by immunohistochemistry (IHC) using the H-score. The score, given as the sum of the percKeywords
This publication has 22 references indexed in Scilit:
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast CancerJournal of Clinical Oncology, 2011
- Incidence of Breast Cancer in the United States: Current and Future TrendsJNCI: Journal of the National Cancer Institute, 2011
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancerLaboratory Investigation, 2011
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast CancerClinical Cancer Research, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002